Loading...
XLON
SN.
Market cap12bUSD
Mar 24, Last price  
1,239.16GBP
Name

Smith & Nephew PLC

Chart & Performance

D1W1MN
XLON:SN. chart
P/E
33.65
P/S
2.39
EPS
0.49
Div Yield, %
Shrs. gr., 5y
14.86%
Rev. gr., 5y
2.49%
Revenues
5.81b
+4.70%
2,552,000,0002,779,000,0003,369,000,0003,801,000,0003,772,000,0003,962,000,0004,270,000,0004,137,000,0004,351,000,0004,617,000,0004,634,000,0004,669,000,0004,765,000,0004,904,000,0005,138,000,0004,560,000,0005,212,000,0005,215,000,0005,549,000,0005,810,000,000
Net income
412m
+56.65%
333,000,000745,000,000316,000,000377,000,000472,000,000615,000,000582,000,000729,000,000556,000,000501,000,000410,000,000784,000,000767,000,000663,000,000600,000,000448,000,000524,000,000223,000,000263,000,000412,000,000
CFO
987m
+62.34%
260,000,000352,000,000424,000,000566,000,000719,000,000859,000,000842,000,000902,000,000867,000,000683,000,0001,030,000,000849,000,0001,090,000,000931,000,0001,168,000,000935,000,000877,000,000468,000,000608,000,000987,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Smith & Nephew plc, along with its various subsidiary companies, operates globally in the research, development, manufacturing, marketing, and distribution of medical devices. The company's orthopedic reconstruction portfolio includes knee implants designed for total knee replacement surgeries and hip implants used in the reconstruction of hip joints. Additionally, they provide trauma and extremity products, which encompass both internal and external fixation devices essential for stabilizing severe bone fractures and correcting skeletal deformities. For surgical practitioners, Smith & Nephew develops sports medicine joint repair solutions. These offerings feature specialized instruments, advanced technologies, and implants crucial for performing minimally invasive procedures on joints. Such procedures address a range of issues, including soft tissue injuries and degenerative conditions affecting the knee, hip, and shoulder, as well as providing systems for meniscal repair. Furthermore, the company supplies arthroscopic enabling technologies. These consist of fluid management systems for surgical access, high-definition cameras, digital image capture devices, endoscopes, light sources, and monitors, all designed to offer enhanced visualization within joints. They also provide radiofrequency, electromechanical, and mechanical tools for tissue resection, alongside hand instruments for the removal of damaged tissue. Additionally, Smith & Nephew offers ear, nose, and throat (ENT) solutions. In the realm of wound management, Smith & Nephew provides an extensive range of advanced wound care products intended for both the treatment and prevention of acute and chronic wounds. This category covers conditions such as leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Their advanced wound bioactives division includes biologics and other biologically active technologies vital for debridement and promoting dermal repair and regeneration. This also extends to regenerative medicine products, such as substitutes for skin, bone grafts, and articular cartilage. Completing their wound care offerings are advanced wound devices, including traditional and single-use negative pressure wound therapy systems and hydrosurgery systems. The primary customer base for Smith & Nephew plc consists of healthcare providers worldwide. Founded in 1856, the company's corporate headquarters are situated in Watford, United Kingdom.
IPO date
Aug 13, 1951
Employees
19,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT